Stock Analysis
Bavarian Nordic Full Year 2023 Earnings: EPS: kr.19.23 (vs kr.4.93 loss in FY 2022)
Bavarian Nordic (CPH:BAVA) Full Year 2023 Results
Key Financial Results
- Revenue: kr.7.06b (up 124% from FY 2022).
- Net income: kr.1.48b (up from kr.347.4m loss in FY 2022).
- Profit margin: 21% (up from net loss in FY 2022).
- EPS: kr.19.23 (up from kr.4.93 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bavarian Nordic Earnings Insights
Looking ahead, revenue is expected to decline by 4.6% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 19%.
Performance of the market in Denmark.
The company's shares are up 7.3% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Bavarian Nordic (1 is potentially serious!) that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether Bavarian Nordic is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:BAVA
Bavarian Nordic
Develops, manufactures, and commercializes life-saving vaccines.
Flawless balance sheet and undervalued.